Balchem Q3 2026 slides: record quarter, 29th straight EBITDA gain
Balchem (NASDAQ: BCPC) reported Q3 2026 sales of $290.7M (+8.6% YoY), adjusted EBITDA of $80.3M (+12.4%), and adjusted EPS of $1.57 (+16.3%). The company marked its 29th consecutive quarter of EBITDA growth, with all three segments contributing. Shares traded at $174.65, up 0.82%.
How this was made
The 30-second read
Why it matters
Earnings beat and strong cash generation suggest near‑term price appreciation.
Market read
First‑time earnings disclosure with material beat, relevant for traders seeking short‑term upside.
What to watch
Potential headwinds from raw material costs and macro slowdown could temper momentum.
Background
Balchem presented its Q3 2026 investor deck, emphasizing record performance and dividend growth.
Ticker impact
Q3 2026 earnings beat estimates with 12.4% EBITDA growth and 16.3% EPS increase, driving a 0.8% share rise.
upward pressure as market prices in the earnings beat and strong guidance.
First report of the quarter's results, beat on both earnings and guidance, with solid cash flow and low leverage.
Market effects
Highlights strength in nutrition and health specialty ingredients, may boost peer segment sentiment.
Positive for US mid‑cap consumer‑industrial stocks.
Shows resilience in food‑tech supply chains, modest global relevance.
Counterpoint
Valuation may already price in growth; upside limited if guidance softens later.
Key entities
- companyBalchem Corporation
US‑listed nutrition and health specialty ingredients producer.